EVM
RVMD icon

Eaton Vance Management’s Revolution Medicines RVMD Stock Holding History

Eaton Vance Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-126
Closed -$6K – 2985
2021
Q1 		$6K Buy
+126
New +$5.65K ﹤0.01% 2532

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Eaton Vance Management's RVMD Position: Q2 2021 in Review

Eaton Vance Management sold out of Revolution Medicines (RVMD) in Q2 2021, closing a stake of 126 shares — an estimated $6K sold.

Eaton Vance Management first reported a position in RVMD in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 130 funds tracked by Wall St. Rank hold RVMD as of Q2 2021.

  • Eaton Vance Management reported no remaining Revolution Medicines position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 126 Revolution Medicines shares in Q2 2021, an estimated $6K.
  • Eaton Vance Management first reported a position in Revolution Medicines in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Revolution Medicines position peaked at $6K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.